Neurologic Disorders Therapeutics - Global Strategic Business Report

The global market for Neurologic Disorders Therapeutics was estimated at US$116.4 Billion in 2023, and is projected to reach US$149.7 Billion by 2030, growing at a CAGR of 3.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the neurologic disorders therapeutics market is driven by several factors. Firstly, the increasing prevalence of neurologic conditions, particularly among aging populations, has heightened the demand for effective treatments. Secondly, advancements in biotechnology and pharmaceutical research are continuously leading to the development of new and improved therapies, including gene therapies and neuroprotective agents. The expansion of healthcare infrastructure in emerging markets has also facilitated better access to neurologic care, contributing to market growth. Additionally, strategic collaborations between pharmaceutical companies, academic institutions, and research organizations are accelerating the discovery and commercialization of innovative treatments. The rise of digital health technologies, including telemedicine and wearable devices, is enhancing patient monitoring and management, leading to better outcomes. Lastly, increased funding for neurologic research and the development of comprehensive treatment guidelines are fostering a more structured and effective approach to managing neurologic disorders.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Anticholinergic Drug Class segment, which is expected to reach US$45.2 Billion by 2030 with a CAGR of a 4.0%. The Analgesics Drug Class segment is also set to grow at 4.4% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $31.7 Billion in 2023, and China, forecasted to grow at an impressive 7.0% CAGR to reach $31.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Neurologic Disorders Therapeutics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Neurologic Disorders Therapeutics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Neurologic Disorders Therapeutics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as AstraZeneca PLC, Biogen, Inc., Biohaven, Ltd., and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

• AstraZeneca PLC
• Biogen, Inc.
• Biohaven, Ltd.
• Eisai Co., Ltd.
• H. Lundbeck A/S
• Ionis Pharmaceuticals, Inc.
• Mitsubishi Tanabe Pharma Corporation
• Neurelis, Inc.
• Neurocrine Biosciences, Inc.
• Neurona Therapeutics, Inc.
• Ovid Therapeutics, Inc.
• Pfizer, Inc.
• Sanofi SA
• UCB SA
• Voyager Therapeutics, Inc.